The use of the ACTH stimulation test, or short synacthen test (SST), has been growing in popularity, 1, 2 and is the most widely used investigation of adrenocortical function in some countries. 3 It is increasingly being considered increasingly as the "standard" for the diagnosis of adrenal insufficiency. [4] [5] [6] The SST mimics the ACTH stimulus to the adrenal cortex and involves administration of either high-dose supraphysiological 250 μg or low-dose physiological, usually 1 μg, synacthen. Both the high-and low-dose tests are used in clinical practice, and results of meta-analyses do not show significant superiority of 1 test over the other. [7] [8] [9] [10] [11] Worldwide clinician preference for adrenal function testing and the popularity of the high-and low-dose SST are unknown. We report the results of an international survey, of both paediatric and adult endocrinologists, to assess current practice. Alexandra S. Cross and E. Helen Kemp contributed equally to the study. Methods: Members of 6 international endocrine societies were surveyed regarding diagnostic tests used for adrenal insufficiency, and in particular the SST. Synacthen was diluted for the LDT and concentrations measured using a synacthen ELISA.
One form of diagnostic-grade synacthen is commercially available, manufactured in 250 μg/mL ampoules, necessitating large dilutions if administration of a low dose is required. A British survey of paediatric endocrinologists in 2012 reported that, amongst the 82% of respondents who use the low-dose test, 14 different dilution methods were used. 3 These varied in the amount of synacthen utilised for the initial dilution (0.1-1 mL), the volume of the diluent (10 mL-1 L), the diluent type (5% dextrose and 0.9% saline) and the number of dilution steps (1, 2 or 3) employed to prepare the required concentration. 3 There is a paucity of literature on the accuracy or reproducibility of making up low-dose synacthen. The majority of related work pertains to the analysis of adsorptive losses on glass and plastic equipment during the dilution process, with losses proportionate to the length of the plastic device used for administration. [12] [13] [14] We addressed this important clinical issue in an in vitro study and reported the accuracy and reliability of making up 1 μg doses of synacthen by ten of the different methods currently in use.
| MATERIAL S AND ME THODS

| International survey
A thirteen-question online survey (Appendix S1) was distributed to the members of 6 endocrine learned societies with a total of 6744 members: the USA-based Pediatric Endocrine Society (PES, n = 1381), A follow-up reminder was sent after the initial email. Respondents were given the choice of completing the survey using an online surveying platform (https://surveyplanet.com) or an emailed Microsoft Word™ document. Minor changes were made to the survey to meet the various stipulations of the societies.
| Low-dose synacthen dilution study
Results from the 2012 survey of British paediatric endocrinologists were used to investigate precision and accuracy of the ten most commonly employed dilution methods for making up 1 μg low-dose synacthen (Table 1) . 3 Each dilution protocol was followed and the resultant solution made up 5 times to evaluate intramethod variability. In the 9 methods yielding a sufficient final solution, three 1 mL samples were taken (from the top, middle and bottom of the bag of diluent or the syringe) to assess any variation that may be caused by insufficient mixing. Samples were extracted from the superior quar-TA B L E 1 Dilution methods used to make up 1 μg synacthen dose and intramethod variability incubation at room temperature for 45 minutes, the reaction was stopped by the addition of 100 μL of 0.5 mol/L hydrochloric acid.
A Labtech LT4500 spectrophotometer (Labtech International Ltd., Uckfield, UK) was used to read absorption of the wells at 450 nm.
Synacthen concentrations (pg/mL) were estimated from standard curves and corrected by the appropriate dilution factor (50-1000 times) to give the expected concentration in the synacthen solution used to deliver a 1 μg dose ( Table 1 ). All samples were assayed 4 to 6 times, and the mean synacthen concentration determined.
The intra-assay coefficient of variation (CV) was 1.70% at 2500 pg/mL, 1.69% at 5000 pg/mL and 2.35% at 7500 pg/mL. The interassay CV was 4.54% at 5000 pg/mL.
| Statistical analyses
Summary statistics of frequency (%) and mean were used to analyse survey data. Free-text responses detailing the clinical scenarios in which the HDT or LDT were used were categorised into themes using content analysis. For each of the ten dilution methods studied in the low-dose synacthen dilution analysis, intramethod and intrabag/ syringe variance was calculated and expressed as mean, SD and CV. was chosen as the acceptable range for deliverable synacthen dose values to fall within, reflecting standard laboratory practice.
| RE SULTS
| International survey
Responses were received from 766 society members (11% overall response rate), working in 60 countries (single response received from
countries). Response rates varied between the societies: PES, 21%
(n = 290), SfE, 19% (n = 220), ESE, 13% (n = 220), ESPE, 3% (n = 36), ESA, <1% (n = 7) and APEG, 4% (n = 13). Responses were received from clinicians working in the USA (36%), UK (29%), mainland Europe (25%), North America (excluding the USA; 4%), Asia (3%), Australasia (3%), Africa (<1%) and South America (<1%). Endocrinologists who worked mainly or entirely with adults made up 52% of respondents and 45% worked mainly or entirely with children and/or adolescents (97% of USA respondents). The remaining 3% of respondents either did not indicate their patient base or were not clinicians.
The SST was the most popular test for assessing adrenal insufficiency (Table 2 ). It was used by 98% overall with 92% using the HDT, 43% the LDT and 37% both. The LDT was considerably more popular amongst paediatric endocrinologists (72%) compared with adult endocrinologists (17% Respondents stated their rationale for using the HDT or LDT: the most popular reasons for using the HDT were diagnosis of primary adrenal insufficiency and congenital adrenal hyperplasia, or because it was standard procedure. The LDT was preferred to investigate secondary adrenal insufficiency. The majority administer the HDT by the intravenous route (81%), with 37% and 5% using intramuscular and subcutaneous routes, respectively.
Thirty different combinations of cortisol sampling times were specified for the HDT and 37 for the LDT ( Serum cortisol levels without stimulation were used in the diagnosis of adrenal insufficiency by 76% ( CVs of over 10% ( Table 1 ). The least variable was method 6, with a CV of 2.1%; the most variable was method 10, with a CV of 109%.
Optimal dilution would have yielded synacthen concentrations able to deliver a dose close to 1 μg (acceptable range, 0.9-1.1 μg).
However, the method means ranged from 0.16 μg (least accurate) to 0.81 μg (most accurate; Table 1 ). The methods bearing results closest to the range chosen as acceptable were 1, 4 and 6 ( Figure 2 ).
Three methods (7, 9 and 10) had a mean concentration of less than half the expected dose ranging from 0.16 to 0.36 μg (Figure 2 ), reflecting substantial losses of synacthen. To assess any variation or reduction in synacthen dose resulting from the laboratory dilutions necessary for the ELISA quantification, 2 vials of synacthen (250 μg/ mL) were diluted and samples run over 23 assays. This yielded results of 247 ± 11 μg/mL and 223 ± 12 μg/mL, and indicated that the wide variation in deliverable dose detected in samples was not due to inaccuracies in the required laboratory dilutions. 
| D ISCUSS I ON
This is the largest international survey of diagnostic tests for adrenal insufficiency to date. Although the response rate of 11% was low, this was a survey of society members some of whom are not in clinical practice and the response rate is in keeping with similar internet surveys. 15, 16 3 This may reflect respiratory guidelines, which recommend the LDT for assessment of adrenal function in children on inhaled corticosteroids.
18,19
The sampling times and diagnostic cut-offs practised by the majority of respondents were in keeping with Endocrine Society guidelines, 4 which state a peak cortisol less than 500 nmol/L at 30 or 60 minutes indicates adrenal insufficiency. Deviations from these guidelines were seen in 52% of HDT and 39% LDT users for cut-off and <1% HDT and 5% LDT users for timing. The tendency to employ lower diagnostic thresholds for serum cortisol is likely to reflect a change in practice to locally derived cut-offs, dependent on the assay platform used. Additionally, clinicians review the SST results in the context of the clinical suspicion of adrenal insufficiency. 20, 21 Responses were received from people working in 60 countries This study has shown a high intermethod variability between different commonly employed dilution strategies for the low-dose SST.
The variation in dose was from 0.16 to 0.81 μg when the dose should be 1 μg; thereby in all cases, the dilution methods used provide inadequate dosing, with doses up to 7-fold less than required. There was variation when the same method was used to make up the 1 μg When similar methods (eg volume of diluent, proportion of synacthen ampoule used, number of dilution steps) were grouped and compared, only the initial volume of synacthen was shown to significantly affect the final concentration: dilution methods using the full ampoule gave significantly higher concentrations and closer to the desired concentration. The most accurate and least variable method was the only one to use 5% dextrose, suggesting that dextrose may be the most suitable diluent for making up low-dose synacthen.
However, this would require further investigation along with other possible diluents for synacthen.
The plateau of the synacthen/cortisol dose-response curve is thought to begin at approximately 5 μg of synacthen. 12 The lowest dose of synacthen to maximally stimulate the adrenal gland has been found to be between 0.5 and 1 μg. using 0.2 mL or less, a volume too small to draw up accurately using 1 mL ward syringes.
Intrabag/syringe variability was high but similar between different parts (top, middle, bottom), suggesting mixing inadequacy but no specific area the synacthen settled in. In laboratory practice, mixing of constituents similar to those used in this study may take place over many hours with the use of specialised equipment, to be assured of uniform distribution throughout the diluent.
There is no "standard" way to make up the 1 μg synacthen dose.
The method of adding 250 μg/mL to 250 mL of 0.9% saline (method Other sources of variation have been considered. These include potential losses caused by the adherence of synacthen to plastic, reported to be between 21.6% and 58.6% and proportional to the length of the device. 13, 14 This study made up low-dose synacthen under replicated ward conditions, using plastic syringes. Additional plastic laboratory equipment was used in the dilutions prior to ELISA analysis, potentially adding to the losses. However, the "control" A systematic review has shown preprepared syringes for intravenous medication can reduce errors in the preparation and administration by 21%. 26 Our international survey showed the synacthen test is employed by 98% of endocrinologists, with 43% using the LDT. Our dilution study demonstrated considerable variation and inaccuracy when preparing the low dose of synacthen. The least variable methods were 1, 4 and 6 (Table 1 ). Although method 6 used 5% dextrose, the effect of diluent needs to be investigated further before any recommendations can be made. In addition, it would be expected that controlled laboratory/pharmacy conditions would impact positively on the accuracy of the delivered dose.
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